NHS ENDORSEMENT

Core Diagnostics, Digistain collaborate to bring breast cancer risk profiling technology to India, Nepal, Bhutan, Bangladesh

Digistain is a digital solution for cancer grading and prognosis, approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA). It offers a rapid, affordable, and AI-enabled solution to predict the likelihood of post-surgery breast cancer recurrence. This technology is designed to prevent breast cancer patients from undergoing unnecessary chemotherapy.